EA Mittendorf

615 citations
45 papers · 448 · h-index 8

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • HER2/EGFR in Cancer Research
    • CAR-T cell therapy research
  • Immunology
    • Immunotherapy and Immune Responses

Papers in

  • Oncology 30
    • Cancer Immunotherapy and Biomarkers 13
    • HER2/EGFR in Cancer Research 9
    • Cancer Treatment and Pharmacology 7
  • Cancer Research 25
    • Breast Cancer Treatment Studies 21
    • Cancer Genomics and Diagnostics 7
Co-authors
Sathibalan Ponniah (13 shared papers)Guy T. Clifton (1 shared paper)George E. Peoples (2 shared papers)Erika J Schneble (1 shared paper)Jarrod P. Holmes (5 shared papers)David Van Echo (1 shared paper)Thomas A. Buchholz (4 shared papers)Khandan Keyomarsi (1 shared paper)
Journals
Cancer Research (21 papers)Annals of Oncology (9 papers)Journal of Clinical Oncology (8 papers)ESMO Open (2 papers)JNCI Monographs (1 paper)
Partner nations
United StatesSwitzerlandBrazil

In The Last Decade

EA Mittendorf

42 papers receiving 432 citations

Peers

EA Mittendorf
Comparison fields: 5 of 53
  • Oncology 245
  • Immunology 190
  • Cancer Research 110
  • Radiology, Nuclear Medicine and Imaging 69
  • Pathology and Forensic Medicine 28
Replace Annegé Vledder with:
Annegé Vledder Netherlands
Rikke Løvendahl Eefsen Denmark
Rachel Marty Pyke United States
Filippos Kontos United States
Valerie Jakrot Australia
Serena Zanotta Italy
Ron S. Gejman United States
Puay Hoon Tan Singapore
Obi L. Griffith United States
Zhongmin Maxwell Wang China
EA Mittendorf relative to Annegé Vledder Netherlands Annegé Vledder's profile →
Citations per field
00.5×5×11.5×
Annegé Vledder · 1×
Citations per year

Countries citing papers authored by EA Mittendorf

Since Specialization
Citations

This map shows the geographic impact of EA Mittendorf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by EA Mittendorf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites EA Mittendorf more than expected).

Fields of papers citing papers by EA Mittendorf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by EA Mittendorf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by EA Mittendorf. The network helps show where EA Mittendorf may publish in the future.

Co-authors

The 25 scholars most cited alongside EA Mittendorf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with EA Mittendorf Line = papers co-authored together EA Mittendorf links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
Annals of Oncology ·EA Mittendorf, Guy T. Clifton, Jarrod P. Holmes, Erika J Schneble, David Van Echo, Sathibalan Ponniah, George E. Peoples
2014201
2
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Annals of Oncology ·Gabriele Antonarelli, Chiara Corti, Paolo Tarantino, Liliana Ascione, J. Cortés, Pedro Romero, EA Mittendorf, Mary L. Disis, Giuseppe Curigliano
202149
3
Abstract S2-1: The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial
Cancer Research ·JC Boughey, VJ Suman, EA Mittendorf, GM Ahrendt, LG Wilke, Bret Taback, A. Marilyn Leitch, TS Flippo-Morton, D. Byrd, DW Ollila, TB Julian, SA McLaughlin, Lisa McCall, WF Symmans, HT Le-Petross, BG Haffty, TA Buchholz, KK Hunt
201234
4
Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy
JNCI Monographs ·Thomas A. Buchholz, EA Mittendorf, K. Hunt
201533
5
Comparison of clinicopathologic features and survival in young American women aged 18–39 years in different ethnic groups with breast cancer
British Journal of Cancer ·Pei Jun Liu, Xiang Li, EA Mittendorf, Jiangtao Li, X L Du, Jie He, Yifan Ren, Jin Yang, Kelly K. Hunt, Min Yi
201323
6
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
Breast Diseases A Year Book Quarterly ·EA Mittendorf, Khandan Keyomarsi, K. Hunt
201118
7
LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)
Annals of Oncology ·Nadia Harbeck, H. Zhang, Carlos H. Barrios, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L. Telli, Cristiano Ferrario, Kevin Punie, Frédérique Penault‐Llorca, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Vidya Maiya, Luciana Molinero, S.Y. Chui, EA Mittendorf
202014
8
LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)
ESMO Open ·C.H. Barrios, Nadia Harbeck, H.A. Zhang, Shigehira Saji, Ki‐Hong Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, ML Telli, J-F. Boileau, Kevin Punie, M. Dieterich, Zoe J. Assaf, Tao Xu, M. Liste Hermoso, E. Shearer-Kang, Luciana Molinero, S.Y. Chui, EA Mittendorf
202314
9
Abstract P5-16-02: Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vaccine
Cancer Research ·TJ Vreeland, GT Clifton, DF Hale, AK Sears, Ritesh Patil, JP Holmes, Sathibalan Ponniah, EA Mittendorf, GE Peoples
20125
10
Abstract OT2-07-03: IMpassion031: A phase III study comparing neoadjuvant atezolizumab vs placebo in combination with nab-paclitaxel–based chemotherapy in early triple-negative breast cancer (TNBC)
Cancer Research ·EA Mittendorf, CH Barrios, Nadia Harbeck, David Miles, Shigehira Saji, H Zhang, A. Trinh Duc, Saeed Rafii, C Lai
20185
11
1MO Prognostic and biologic significance of HER2-low expression in early breast cancer
Annals of Oncology ·Paolo Tarantino, Qingchun Jin, N. Tayob, Rinath Jeselsohn, Stuart J. Schnitt, Julie Vincuilla, Tonia Parker, Svitlana Tyekucheva, NU Lin, Melissa E. Hughes, Anna Weiss, Tari A. King, EA Mittendorf, Giuseppe Curigliano, Sara M. Tolaney
20225
12
Local-regional Recurrence with and without Radiation after Neoadjuvant Chemotherapy and Mastectomy for T1-2/N0-1 Breast Cancer Patients
International Journal of Radiation Oncology*Biology*Physics ·T. Yu, EA Mittendorf, Himanshu Nagar, Pedro J. Prada Gómez, Eric A. Strom, G.H. Perkins, Julia Oh, Welela Tereffe, Wendy A. Woodward, Thomas A. Buchholz
20084
13
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer
Journal of Clinical Oncology ·Abigail S. Caudle, Ana M. González-Angulo, H. K. Kelly, P. Liu, L. Pusztai, W. Fraser Symmans, Henry M. Kuerer, EA Mittendorf, G. N. Hortobagyi, Funda Meric‐Bernstam
20094
14
Early results of a phase I clinical trial of an Ii-Key/Her2/neu MHC class II peptide-based vaccine in breast cancer patients
Journal of Clinical Oncology ·EA Mittendorf, Steven Khoo, Catherine E. Storrer, Katie Harris, Yusuf Jama, Zia A. Dehqanzada, James L. Murray, Craig D. Shriver, Eric von Hofe, Sathibalan Ponniah, George E. Peoples
20063
15
P1-13-01: An Update of a Phase II Trial of the HER2 Peptide AE37 Vaccine in Breast Cancer Patients To Prevent Recurrence.
Cancer Research ·DF Hale, Solene Perez, AK Sears, GT Clifton, TJ Vreeland, JP Holmes, Alexandros Ardavanis, NF Pistamaltzian, G Rellias, Sathibalan Ponniah, Michael Papamichail, GE Peoples, EA Mittendorf
20113
16
Young Women with Locally Advanced Breast Cancer Who Achieve Breast Conservation after Neoadjuvant Chemotherapy Have a Low Local Recurrence Rate
Breast Diseases A Year Book Quarterly ·Sarah M. Gainer, EA Mittendorf
20122
17
3MO IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemo in early triple-negative breast cancer (TNBC)
Annals of Oncology ·Shigehira Saji, EA Mittendorf, Nadia Harbeck, H. Zhang, C.H. Barrios, Raymond Victor Hegg, Andreas Koehler, J. Sohn, Hitoshi Iwata, ML Telli, C. Ferrario, Kevin Punie, F. Penault Llorca, S. Patel, Anh Nguyen Duc, M. Liste Hermoso, V. Maiya, L. Molinero, S. Chui, Keun‐Hwa Jung
20202
18
Local-regional recurrence with and without radiation after neoadjuvant chemotherapy and mastectomy for T3N0 breast cancer patients.
Cancer Research ·Himanshu Nagar, EA Mittendorf, EA Strom, G.H. Perkins, J.H. Oh, Welela Tereffe, Wendy A. Woodward, AM Gonzalez-Angulo, Katie N. Hunt, Thomas A. Buchholz, T. Yu
20092
19
Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer.
Cancer Research ·Luca Dominici, V. Negron Gonzalez, Aman U. Buzdar, Anthony Lucci, EA Mittendorf, Lajos Pusztai, (unknown), HT Le-Petross, Gildy V. Babiera, I. Bedrosian, Funda Meric‐Bernstam, Katie N. Hunt, Vicente Valero, Henry M. Kuerer
20092
20
Abstract OT2-01-14: Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489)
Cancer Research ·JK Litton, Stacy L. Moulder, Thorunn Helgason, AR Clayborn, GM Rauch, Michael Z. Gilcrease, BE Adrada, Lei Huo, KR Hess, WF Symmans, Alan J. Thompson, Debu Tripathy, EA Mittendorf
20172

About EA Mittendorf

EA Mittendorf is a scholar working on Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging, Immunology and Pulmonary and Respiratory Medicine, having authored 45 papers that have together received 448 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (21 papers), Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (12 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), HER2/EGFR in Cancer Research (9 papers), Advanced Breast Cancer Therapies (8 papers), Cancer Genomics and Diagnostics (7 papers) and Cancer Treatment and Pharmacology (7 papers). The work is most often cited by research in Oncology (245 citations), Immunology (190 citations), Cancer Research (110 citations), Radiology, Nuclear Medicine and Imaging (69 citations) and Pathology and Forensic Medicine (28 citations). EA Mittendorf has collaborated with scholars based in United States, Switzerland and Brazil. Frequent co-authors include Sathibalan Ponniah, Guy T. Clifton, George E. Peoples, Erika J Schneble, Jarrod P. Holmes, David Van Echo, Thomas A. Buchholz, Khandan Keyomarsi, Chiara Corti and Paolo Tarantino. Their work appears in journals such as Cancer Research, Annals of Oncology, Journal of Clinical Oncology, ESMO Open and JNCI Monographs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annegé VledderBreakdown of academic impact, for papers by Rikke Løvendahl EefsenBreakdown of academic impact, for papers by Rachel Marty PykeBreakdown of academic impact, for papers by Filippos KontosBreakdown of academic impact, for papers by Valerie JakrotBreakdown of academic impact, for papers by Serena ZanottaBreakdown of academic impact, for papers by Ron S. GejmanBreakdown of academic impact, for papers by Puay Hoon TanBreakdown of academic impact, for papers by Obi L. GriffithBreakdown of academic impact, for papers by Zhongmin Maxwell Wang